JP2020524162A5 - - Google Patents

Info

Publication number
JP2020524162A5
JP2020524162A5 JP2019570491A JP2019570491A JP2020524162A5 JP 2020524162 A5 JP2020524162 A5 JP 2020524162A5 JP 2019570491 A JP2019570491 A JP 2019570491A JP 2019570491 A JP2019570491 A JP 2019570491A JP 2020524162 A5 JP2020524162 A5 JP 2020524162A5
Authority
JP
Japan
Prior art keywords
dosage form
saliva
composition according
acid
amount
Prior art date
Application number
JP2019570491A
Other languages
English (en)
Japanese (ja)
Other versions
JP7297685B2 (ja
JPWO2018236678A5 (https=
JP2020524162A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/037698 external-priority patent/WO2018236678A1/en
Publication of JP2020524162A publication Critical patent/JP2020524162A/ja
Publication of JPWO2018236678A5 publication Critical patent/JPWO2018236678A5/ja
Publication of JP2020524162A5 publication Critical patent/JP2020524162A5/ja
Application granted granted Critical
Publication of JP7297685B2 publication Critical patent/JP7297685B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019570491A 2017-06-20 2018-06-15 唾液中でメラトニンを可溶性にする酸性化剤を有する経口溶解メラトニン製剤 Active JP7297685B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762522473P 2017-06-20 2017-06-20
US62/522,473 2017-06-20
PCT/US2018/037698 WO2018236678A1 (en) 2017-06-20 2018-06-15 Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva

Publications (4)

Publication Number Publication Date
JP2020524162A JP2020524162A (ja) 2020-08-13
JPWO2018236678A5 JPWO2018236678A5 (https=) 2022-08-03
JP2020524162A5 true JP2020524162A5 (https=) 2022-08-03
JP7297685B2 JP7297685B2 (ja) 2023-06-26

Family

ID=64656010

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019570491A Active JP7297685B2 (ja) 2017-06-20 2018-06-15 唾液中でメラトニンを可溶性にする酸性化剤を有する経口溶解メラトニン製剤

Country Status (13)

Country Link
US (4) US10500280B2 (https=)
EP (1) EP3641759B1 (https=)
JP (1) JP7297685B2 (https=)
KR (1) KR20200018652A (https=)
CN (1) CN110913853A (https=)
AU (1) AU2018289284A1 (https=)
BR (2) BR122021012549B8 (https=)
CA (1) CA3067822C (https=)
ES (1) ES2979335T3 (https=)
MX (1) MX2019015733A (https=)
RU (1) RU2020101742A (https=)
SG (1) SG11201912172YA (https=)
WO (1) WO2018236678A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201912172YA (en) 2017-06-20 2020-01-30 Physicians Seal Llc Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
US10828254B2 (en) 2018-09-28 2020-11-10 Intelgenx Corp. Oral film formulation for modulating absorption profile
CN112426408B (zh) * 2020-12-08 2023-12-19 广州帝奇医药技术有限公司 一种褪黑素组合物及其制备工艺
WO2022170442A1 (en) * 2021-02-12 2022-08-18 Intelgenx Corp. Novel tryptamine oral film formulation
CA3221463A1 (en) * 2021-06-09 2022-12-15 Agb-Pharma Ab Melatonin formulation in solid dosage form
US12440472B2 (en) 2021-06-16 2025-10-14 Intelgenx Corp. Stable tryptamine oral films

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091629A1 (en) 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6730330B2 (en) 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
WO2003074029A1 (en) * 2002-03-07 2003-09-12 Vectura Limited Fast melt multiparticulate formulations for oral delivery
CA2551637A1 (en) 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
JP5179757B2 (ja) 2004-02-17 2013-04-10 トランセプト ファーマシューティカルズ， インコーポレイティド 口腔粘膜を介して催眠剤をデリバリーするための組成物及びその使用方法
US20090047347A1 (en) 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
CA2582299A1 (en) 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
CN101132769A (zh) * 2005-02-10 2008-02-27 奥瑞克索股份公司 用于药物的跨黏膜给药的药物组合物
JP2009527504A (ja) 2006-02-23 2009-07-30 イオメディックス スリープ インターナショナル エスアールエル 良質な睡眠の誘導および維持のための組成物および方法
IL175338A0 (en) * 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
US20080171085A1 (en) 2007-01-11 2008-07-17 Natrol, Inc. Novel biphasic delivery system for a pharmaceutical or nutraceutical composition and method of administration
RU2485949C2 (ru) 2007-04-11 2013-06-27 Фармасьютикал Продакшнс Инк Таблетка мелатонина и способы изготовления и применения
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
CA2685591A1 (en) 2007-05-01 2008-11-06 Sigmoid Pharma Limited Pharmaceutical nimodipine compositions
KR100905027B1 (ko) 2007-10-03 2009-06-30 (주)씨엘팜 식용 필름
EP2265259A1 (en) * 2008-04-25 2010-12-29 Cadila Healthcare Limited Rapidly disintegrating oral compositions of tramadol
US8691275B2 (en) * 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US20120213855A1 (en) 2011-02-17 2012-08-23 Cima Labs Inc. Dosage forms for weakly ionizable compounds
US20120315337A1 (en) * 2011-06-07 2012-12-13 Shah Syed Multiparticulate 5-htp compositions and related methods
US20130052234A1 (en) * 2011-08-25 2013-02-28 Purebrands LLC Edible strips
ES2457718B1 (es) 2012-09-24 2015-04-16 Universidad De Granada Composición farmacéutica bucodispersable de melatonina
US20140303227A1 (en) 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
EP3265140B1 (en) * 2015-03-02 2021-05-12 Medlab Clinical U.S., Inc. Transmucosal and transdermal delivery systems
SG11201912172YA (en) * 2017-06-20 2020-01-30 Physicians Seal Llc Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva

Similar Documents

Publication Publication Date Title
JP2020524162A5 (https=)
JP2018517715A5 (https=)
US20250120919A1 (en) Compositions of midodrine and methods of using the same
JP2004501190A5 (https=)
PE20110855A1 (es) Forma de dosificacion oral de liberacion prolongada de acetaminofeno/tramadol
RU2020101742A (ru) Растворяющаяся во рту лекарственная форма мелатонина с подкисляющей добавкой, которая делает мелатонин растворимым в слюне
JP2010504993A5 (https=)
JP2011520965A5 (https=)
JP2018521985A5 (https=)
CN109985016B (zh) 一种非布司他的控释组合物及其制备方法
JP2005528430A5 (https=)
JP2013147470A (ja) 口腔内崩壊錠
JP2014221827A5 (https=)
NO341573B1 (no) Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen
JP2021529829A5 (https=)
JP2011520980A5 (https=)
JP5466880B2 (ja) 口腔内崩壊錠
JPWO2018236678A5 (https=)
JP2013523628A5 (https=)
JP6623753B2 (ja) 炭酸ランタンを含む口腔内崩壊錠
CN101711792B8 (zh) 一种治疗冠心病的滴丸及其制备方法
JP2015521647A5 (https=)
JP5572321B2 (ja) 被覆微粒子含有口腔内崩壊錠
TW201318650A (zh) 口崩片組成物
CO6351711A2 (es) Combinacion de dosis fija en la forma de una tableta de dos copas o de una sola capa de alisquireno y amlodipina